

We Claim:

- 1 1. (Original) Amorphous rosuvastatin magnesium.
- 1 2. (Original) Amorphous rosuvastatin magnesium having purity greater than 99%  
2 with diastereomeric impurity less than 0.5%.
- 1 3. (Original) Amorphous rosuvastatin magnesium according to claim 2 having purity  
2 greater than 99.5% with diastereomeric impurity less than 0.25%.
- 1 4. (Original) Amorphous rosuvastatin magnesium according to claim 3 having purity  
2 greater than 99.8% with diastereomeric impurity less than 0.15%.
- 1 5. (Original) Amorphous rosuvastatin magnesium substantially free of crystalline  
2 rosuvastatin magnesium.
- 1 6. (Original) A process for the preparation of crystalline rosuvastatin magnesium  
2 comprising:
  - 3 a) treating rosuvastatin methyl ammonium salt or rosuvastatin lactone with a  
4 base and magnesium salt; and
  - 5 b) isolating crystalline rosuvastatin magnesium from the reaction mass.
- 1 7. (Cancelled)
- 1 8. (Cancelled)
- 1 9. (Original) A process for preparing amorphous rosuvastatin magnesium  
2 comprising:
  - 3 a) dissolving crystalline rosuvastatin magnesium in a first organic solvent;
  - 4 b) adding a second organic solvent to the solution of rosuvastatin magnesium  
5 or adding the solution of rosuvastatin magnesium to the second organic  
6 solvent (in optional order of succession) wherein rosuvastatin magnesium is  
7 insoluble or very slightly soluble or sparingly soluble in the second solvent,  
8 such that amorphous rosuvastatin magnesium precipitates; and

- 9           c)       isolating amorphous rosuvastatin magnesium.
- 1   10.   (Original) A process for preparing amorphous rosuvastatin magnesium  
2       comprising:
- 3           a)       dissolving crystalline rosuvastatin magnesium in an organic solvent;
- 4           b)       adding water to the solution of rosuvastatin magnesium, or adding the  
5                solution of rosuvastatin magnesium to water (in optional order of  
6                succession), such that rosuvastatin magnesium precipitates; and
- 7           c)       isolating amorphous rosuvastatin magnesium.
- 1   11.   (Cancelled)
- 1   12.   (Original) A process for preparing amorphous rosuvastatin magnesium  
2       comprising:
- 3           a)       dissolving crystalline rosuvastatin magnesium in an organic solvent  
4                optionally containing water; and
- 5           b)       freeze drying or lyophilizing the solution to get amorphous rosuvastatin  
6                magnesium.
- 1   13.   (Cancelled)
- 1   14.   (Cancelled)
- 1   15.   (Cancelled)
- 1   16.   (Original) A process for preparing rosuvastatin calcium comprising:
- 2           a)       treating amorphous rosuvastatin magnesium with a base and a calcium salt;  
3                and
- 4           b)       isolating rosuvastatin calcium from the reaction mass.
- 1   17.   (Cancelled)

- 1 18. (Original) Pharmaceutical composition to be used as HMG-CoA reductase  
2 inhibitor in treatment of hyperlipidemia comprising amorphous rosuvastatin  
3 magnesium.
- 1 19. (Original) A method for inhibiting HMG-CoA enzyme in treatment of  
2 hyperlipidemia, comprising administering to a mammal in need thereof a  
3 therapeutically effective amount of amorphous rosuvastatin magnesium.